NGM Bio to Present at the Cowen 41st Annual Health Care Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NGM Biopharmaceuticals (NGM) will present a business update at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 11:10 am ET. CEO David J. Woodhouse, Ph.D., will lead the presentation. Interested parties can access a live webcast on the company's website, with a replay available for 30 days following the event. NGM focuses on developing innovative therapeutics targeting liver, metabolic, retinal diseases, and cancer, utilizing a biology-centric drug discovery approach to accelerate clinical development.
Details
News Market Reaction – NGM
The recorded move for NGM in the trading session of this news was -9.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the Cowen 41st Annual Health Care Conference on Thursday, March 4, at 11:10 am ET.
A live webcast of the presentation will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contact: Alex Schwartz ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.